NAVIDEA BIOPHARM. DL-001 – Filings and Transcripts – BamSEC

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

SEC EDGAR

Financials Filter

ended 09/30/23 Q3

ended 06/30/23 Q2

ended 03/31/23 Q1

ended 12/31/22 FY 2022

ended 09/30/22 Q3

Prospectuses and Registrations Filter

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Updated info for already-effective prospectus

Ownership Filter

Scott John K Jr.

Scott John K Jr.

Scott John K Jr.

Stefanelli Jill

News Filter

Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release

Material Definitive Agreement, Unregistered Sales of Equity Securities, Change in Directors, Officers or Compensation, Shareholder Vote Results, Financial Statements or Exhibits

Change in Directors, Officers or Compensation, Financial Statements or Exhibits

Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer

Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Preliminary proxy

Definitive proxy

Preliminary proxy

Other Filter

Notice of effectiveness

Notice of effectiveness

Notice of effectiveness

Notice of effectiveness

Notice of effectiveness